Wargo, French & Singer LLP partner Alina Singer and associate Aaron Bibbee represented a multinational Fortune 100 pharmaceutical company in connection with the renewal and consolidation of a large‑scale, cross‑supply arrangement with another multinational Fortune 500 pharmaceutical company governing the manufacture, purchase, and supply of finished pharmaceutical products and related active pharmaceutical ingredients. The transaction, valued at $200M, refreshed and streamlined legacy manufacturing and supply frameworks into harmonized, forward‑looking agreements designed to support long‑term commercial stability while preserving flexibility in a volatile regulatory and market environment.The matter highlights the firm’s ability to navigate complex pharmaceutical supply relationships and to craft commercially precise contract architecture tailored to high‑value, long‑duration arrangements.